Download Christopher Vinnard - Public Health Research Institute

Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
Office Address:
Public Health Research Institute
New Jersey Medical School
Rutgers, The State University of New Jersey
225 Warren Street
Newark, NJ 07103
Education:
05/1995
05/2002
05/2002
05/2010
B.A. (magna cum laude)
M.D.
M.P.H.
M.S.C.E.
Amherst College (Physics)
Tulane University School of Medicine
Tulane School of Public Health and Tropical Medicine
Center for Clinical Epidemiology and Biostatistics,
University of Pennsylvania
Postgraduate Training and Fellowship Appointments:
07/2002-06/2003
Intern in Medicine, New York University, New York City
07/2003-06/2005
Resident in Medicine, New York University, New York City
07/2007-06/2011
Fellowship, Infectious Diseases, Hospital of the University of
Pennsylvania, Philadelphia
Hospital and Administrative Appointments:
7/2005-8/2005
Attending Physician, Indian Health Service, Pine Ridge, South Dakota
8/2005-10/2005
Attending Physician, Ketchikan General Hospital, Ketchikan, Alaska
11/2005-12/2005
Attending Physician, Walker Baptist Memorial Hospital, Jasper, Alabama
5/2006-6/2007
Attending Physician, Gouverneur Healthcare Services, New York, NY
7/2009- 6/2011
Attending Physician, Philadelphia VAMC, Philadelphia, PA
7/2011- 2/2016
Assistant Professor, Drexel University College of Medicine, Philadelphia, PA
2/2016- present
Assistant Professor, New Jersey Medical School, Newark, NJ
Other Activities
1/2006-4/2006 Foreign language study and travel, Liaocheng University, China
Other Appointments:
1995-1996
Lecturer in Mathematics, Temasek Polytechnic, Singapore
1997-1998
Instructor of English as a Second Language, Venezuela
Specialty Certification:
2005
Diplomate, American Board of Internal Medicine
2007
Certificate of Knowledge in Clinical Tropical Medicine and Travelers’
Health, American Society of Tropical Medicine and Hygiene
2009
Diplomate in Infectious Diseases, American Board of Internal Medicine
Active Licensure:
Pennsylvania (No. 431922)
Memberships in Professional & Scientific Societies:
2011-present
Member, American Medical Association
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
2014-present
Member, Infectious Disease Society of America
Awards, Honors, and Membership in Honorary Societies:
2009
Robert Austrian Award for Outstanding Fellow, Division of Infectious
Diseases, University of Pennsylvania School of Medicine
2009
NIH Loan Repayment Program Award
2010
Scholarship Award, 26th International Conference on Pharmacoepidemiology
2010
Infectious Disease Fellows Grant, 50th Interscience Conference of
Antimicrobial Agents and Chemotherapy
2010
Fellows Travel Grant, 48th Annual Meeting of the Infectious Disease Society of
America
2010
Special Citation for Fellows-in-Training, 48th Annual Meeting of the Infectious
Disease Society of America
2011
NIH Loan Repayment Program Award (competitive renewal)
2012
Citation for “among the best reviews of 2011”, Pharmacoepidemiology and
Drug Safety
2013
NIH Loan Repayment Program Award (competitive renewal)
2015
Excellence in Teaching Award, Department of Family Medicine, Drexel
University College of Medicine
Educational Activities:
2006-2007
Doctoring course for medical students, New York University School of
Medicine
2008-2011
Infectious disease elective for medical students, University of
Pennsylvania School of Medicine
2011-2016
Core curriculum courses, Infectious Disease Fellowship, Drexel University
College of Medicine
2011-2016
Lecturer, HIV Medical Management Course, Drexel University College of
Medicine
2012-2016
Resident Lecture Series, Principles of Biomedical Research, “Biomedical
Research Ethics: Case Studies and Quandries”
2012-2016
Lecturer, Internal Medicine Board Review, Skin and Soft Tissue
Infections, Drexel University College of Medicine
2015-2016
Lecturer, Internal Medicine Board Review, Invasive Fungal Infections, Drexel
University College of Medicine
Editorial Activities:
2009-present
Peer Reviewer:
1. Emerging Infectious Diseases
2. Journal of Infection
3. BMC Public Health
4. Clinical Infectious Diseases
5. BMC Infectious Disease
6. Pharmacoepidemiology and Drug Safety
7. Transplant Infectious Diseases
8. Clinical and Developmental Immunology
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
9. Epidemiology and Infection
10. Infectious Disease Reports
11. Nicotine & Tobacco Research
12. Infectious Diseases
13. Transplant International
14. American Journal of Respiratory and Critical Care Medicine
15. Annals of the American Thoracic Society
16. Public Health Reports
Other Service Related to Professional Work:
2012-2015
External Reviewer of AIDS-defining events, AIDS Clinical Trials Group
(ACTG) study A5274
2014
Peer reviewer, Medical Research Council, UK
2014-2016
Member, Tuberculosis Transformative Science Group, ACTG
2015
Peer reviewer, British Society for Antimicrobial Chemotherapy Grants
Program, UK
2016
Review panel member, Brody Family Medical Trust Fund, College of Physicians
of Philadelphia
Invited Lectures:
October 2009
Tuberculous Meningitis in the United States 1993-2005: Risk factors for initial
Isoniazid resistance, and the association of initial isoniazid resistance with
mortality. Centers for Disease Control, Division of Tuberculosis Elimination,
Surveillance and Epidemiology Branch, Atlanta, GA
November 2010 Drug Resistant Tuberculous Meningitis: How clinical pharmacology can
provide the framework for an epidemiologic investigation. Society for Clinical
and Biomedical Research, Philadelphia, PA
March 2011
Risk Factors for Nontuberculous Mycobacterial Infections in Solid Organ
Transplant Recipients. Penn Center for Education and Research on
Therapeutics (PennCERT), Philadelphia, PA
March 2013
Tuberculous Meningitis: The Impact of Initial Drug Resistance on Clinical
Outcomes. NYC Department of Health and Mental Hygiene, Office of
Surveillance and Epidemiology, Bureau of Tuberculosis Control, NYC, NY
March 2013
HIV Treatment Update 2013. HIV Planning Council, Philadelphia, PA
May 2013
Tuberculous Meningitis and the BCG Vaccine. North America Vaccine
Development Grand Rounds, GlaxoSmithKline, King of Prussia, PA
June 2013
Novel diagnostic assays for poor anti-tuberculosis drug bioavailability. Clinical
Research Conference, Division of Clinical Pharmacology, Thomas Jefferson
University, Philadelphia, PA
July 2013
HIV/AIDS Associated Opportunistic Infections. Case Management Annual
Medical Update, Philadelphia, PA.
October 2013
IGRAs in the Immunocompromised Patient: Are We Reaching the Tipping
Point? Satellite Symposium, IDWeek, San Francisco, CA.
November 2013 IGRAs in the HIV+ Patient: Are We Reaching the Tipping Point? Association
of Nurses in AIDS Care, Atlanta, GA.
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
June 2015
June 2016
Does Immune Activation Explain Variability in Isoniazid Metabolism in HIVAssociated Tuberculosis? Division of Infectious Diseases Grand Rounds,
University of Pennsylvania, Philadelphia, PA.
Individualized Tuberculosis Therapies and Sutton’s Law. Division of Pulmonary
Medicine Grand Rounds, New York, NY
Abstracts and Presentations:
1. Vinnard C, Longworth S, Lee I, Blumberg E. Risk Factors for Nontuberculous Mycobacterial
Infections in Heart and Lung Transplant Recipients. Poster presentation, 26th International
Conference on Pharmacoepidemiology, Brighton, U.K., 2010.
2. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. Factors associated with isoniazid
resistant tuberculous meningitis in the United States, 1993-2005. Late-breaking poster
presentation, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston,
MA, 2010.
3. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. Tuberculous meningitis in the
United States 1993-2005: The association of initial isoniazid resistance with mortality. Oral
presentation, 48th Annual Meeting of the Infectious Disease Society of America, Washington, D.C.,
2010.
4. Longworth S, Vinnard C, Lee I, Blumberg E. Risk factors for nontuberculous mycobacterial
infections in heart and lung transplant recipients. Poster presentation, 48th Annual Meeting of the
Infectious Disease Society of America, Washington, D.C., 2010.
5. Vinnard C, Lee I, Linkin D. Norovirus outbreak among attendees of a hospital teaching
conference. Poster presentation, Annual Scientific Meeting of the Society for Healthcare
Epidemiology of America, Dallas, TX, 2011.
6. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. Multidrug resistant tuberculous
meningitis in the United States, 1993-2005. Oral presentation, 19th World Congress of
Epidemiology, Edinburgh, U.K., 2011.
7. Vinnard C, Linkin DR, Behrman A. Approach to Latent Tuberculosis among Occupational
Health Providers. Poster presentation, 52nd Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, 2012.
8. Yates F, Linkin DR, Vinnard C. BCG Vaccination and LTBI Treatment Attitudes among Resident
Physicians. Poster presentation, 51st Annual Meeting of the Infectious Disease Society of America,
2013.
9. Adams JW, Allen SW, Vinnard C. Adherence to national guidelines for latent tuberculosis
infection screening among HIV-infected patients in Philadelphia. Poster presentation, International
Epidemiological Association’s World Congress on Epidemiology. Anchorage, AK, 2014.
10. Janakiraman A, Yates F, Headly A, Linkin DR, Vinnard C. Do Resident Physicians Agree with
LTBI Treatment Guidelines? Poster presentation, 52nd Annual Meeting of the Infectious Disease
Society of America, Philadelphia, PA, 2014.
11. Chaudhari S, Vinnard C. Racial Disparities among Tuberculosis Deaths in the United States,
1999-2009. Poster Presentation, 52nd Annual Meeting of the Infectious Disease Society of America,
Philadelphia, PA, 2014.
12. Zentner I, Khensouvann L, Kutzler M, Schlecht H, Bisson GP, Peloquin C, Vinnard C. A Urine
Colorimetric Assay to Detect Low Peak Serum Concentrations of Pyrazinamide: A Proof-ofConcept Study. Poster presentation, 54th Interscience Conference on Antimicrobial Agents and
Chemotherapy, Washington, D.C., 2014.
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
13. Khensouvann L, Meng Z, Baliban S, Kutzler M, Bentz J, Vinnard C. Effect of P-Glycoprotein
Inhibition on Rifampicin Transport Across the Caco-2 Cell Monolayer. Poster presentation, 54th
Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 2014.
14. Khensouvann L, Kutzler M, Gumbo T, Pasipanodya J, Schlecht HP, Bisson GP, Peloquin C,
Vinnard C. Urine Colorimetry to Detect Low Rifampicin Bioavailability: A Proof-of-Concept Study.
Poster presentation, 45th Union World Conference on Lung Health, Barcelona, Spain, 2014.
15. Vinnard C, Proops D, Crossa A, Iwata K, Pasipanodya J, Trieu L, Munsiff S, Ahuja S. The
Long-Term Mortality of Tuberculosis Meningitis Patients in New York City. Poster presentation,
ASM Microbe, Boston, MA, 2016.
16. Andrews A, Adams J, Varhese S, Vinnard C. Factors Associated with Successful Screening
for Latent Tuberculosis Infection with the Interferon Gamma Release Assay in an Urban HIV Clinic.
Poster presentation, ASM Microbe, Boston, MA, 2016.
17. Vinnard C, Manley I, Scott B, Bernui M, Varghese S, Adams J, Kutzler M. A Pilot Study of
Immune Activation and Rifampin Absorption in HIV-Infected Patients. Poster presentation, ASM
Microbe, Boston, MA, 2016.
18. Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, pasipanodya J,
Gumbo T, Peloquin CA, Bisson GP, Vinnard C. Urine Colorimetry to Detect Low Rifampin
Exposure During Tuberculosis Therapy: A Proof-of-Concept Study. Poster presentation, ASM
Microbe, Boston, MA, 2016.
19. Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Kant S, Weissman D, Bisson
GP. Immune Activation and Isoniazid Metabolism in HIV-Associated Tuberculosis. Poster
presentation, ASM Microbe, Boston, MA, 2016.
Publications:
1. Vinnard C, Blumberg E. 2008. Prevention of opportunistic infections in the solid organ
transplant recipient. Infections in Medicine 25(9): 403-415.
2. Kranick SM, Vinnard C, Kolson DL. 2009. Propionibacterium acnes brain abscess appearing
ten years after neurosurgery. Archives of Neurology 66(6): 793-5. PMID: 19506144.
3. Vinnard C, Barton T, Jerud E, Blumberg E. 2009. A report of HHV-6 associated encephalitis in
a solid organ transplant recipient and a review of previously published cases. Liver
Transplantation. 15(10): 1242-6. PMID: 19790143.
4. Vinnard C, Macgregor R. 2009. Tuberculous meningitis in the HIV-infected individual. Current
HIV/AIDS Reports. 6(3): 139-45. PMID: 19589299.
5. Vinnard C, Blumberg E. 2009. Detection of human herpesvirus (HHV)-6 and HHV-7 in
transplant recipients: minding the gap. Transplant Infectious Disease. 11(6): 477-9. PMID:
19891754.
6. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2010. Isoniazid resistance and
death in patients with tuberculous meningitis: retrospective cohort study. British Medical Journal.
341: c4451. PMID: 20819874.
7. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2011. Isoniazid resistant
tuberculous meningitis, United States, 1993-2005. Emerging Infectious Diseases. 17(3): 539-42.
PMID: 21392454.
8. Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2011. Multidrug resistant
tuberculous meningitis in the United States, 1993-2005. Journal of Infection. 63(3):240-2. PMID:
21784099.
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
9. Vinnard C, Lee I, Linkin DR. Successful control of a norovirus outbreak among attendees of a
hospital teaching conference. 2011. American Journal of Infection Control. 40(1):73-4. PMID:
21816511.
10. Vinnard C, Linkin DR, Localio AR, Leonard CE, Teal VL, Fishman NO, Hennessy S. 2012.
Effectiveness of Interventions in Reducing Antibiotic Use for Upper Respiratory Infections in
Ambulatory Care Practices. Population Health Management. In press. PMID 23113630.
11. Vinnard C, Linkin DR, Behrman A. 2012. Current Approach to Latent Tuberculosis Diagnosis
and Treatment Among Medical Center Occupational Health Physicians. Infection Control and
Hospital Epidemiology. 33(12):126205. PMID 23143368.
12. Vinnard C, Gopal A, Linkin DR, Maslow J. 2013. Isoniazid toxicity among an older veteran
population: a retrospective cohort study. Tuberculosis Research and Treatment.
2013;2013:549473. PMID 23365735.
13. Bamford L, Ellenberg JH, Hines J, Vinnard C, Jasani A, Gross R. 2013. Factors associated
with a willingness to accept rapid HIV testing in an urban emergency department. AIDS Behavior.
18(2):250-3. PMID 23536139.
14. Vinnard C, Wileyto EP, Bisson G, Winston C. 2013. First use of multiple imputation with the
National Tuberculosis Surveillance System. Epidemiology Research International. doi:pii:875234.
PMID 23658856.
15. Longworth S, Vinnard C, Sims K, Lee I, Barton T, Blumberg EA. 2014. Risk factors for
nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study.
Transplant Infectious Diseases. 16(1):76-83. PMID 24350627.
16. Cheema S, Vinnard C, Linkin DR. 2013. A Time-Off Incentive Was Not Associated with
Influenza Vaccination Acceptance Among Healthcare Workers. Influenza Research and Treatment.
Doi:10.1155/2013/209491. PMID 23878733.
17. Vetter ML, Wadden TA, Vinnard C, Moore RH, Khan Z, Volger S, Sarwer DB, Faulconbridge
LF; POWER-UP Research Group. 2013. Gender differences in the relationship between symptoms
of depression and high-sensitivity CRP. International Journal of Obesity (London). 37Suppl1:S3843. PMID 23921781.
18. Yates F, Janakiraman A, Headly A, Linkin DR, Vinnard C. 2014. Attitudes towards latent
tuberculosis among physicians in training: the role of BCG vaccination. Journal of Community
Health. PMID 25236656.
19. Caroff DA, Norris AH, Keller S, Vinnard C, Zeitler KE, Lukaszewicz J, Zborowski KA, Linkin
DR. 2014. Catheter-salvage in home infusion patients with central line-associated bloodstream
infection. American Journal of Infection Control. 4(12):1331-3. PMID 25465266.
20. Longworth SA, Blumber EA, Barton TD, Vinnard C. 2015. Nontuberculous mycobacterial
infections after solid organ transplantation: a survival analysis. Clinical Microbiology and Infection.
21(1):43-7. PMID 25636926.
21. Zivich S, Cauterucci M, Allen S, Vetter M, Vinnard C. 2015. Long-term virologic outcomes
following bariatric surgery in patients with HIV. Obesity Research and Clinical Practice. 9(6): 633-5.
PMID 26411387.
22. Arif N, Yousfi S, Vinnard C. 2016. Deaths from Necrotizing Fasciitis in the United States, 20032013. Epidemiology and Infection. 144(6): 1338-44. PMID 26548496.
23. Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya J,
Gumbo T, Peloquin CA, Bisson GP, Vinnard C. 2016. Urine Colorimetry to Detect Low Rifampin
Exposure During Tuberculosis Therapy: A Proof-of-Concept Study. BMC Infectious Diseases. doi:
10.1186/s12879-016-1576-1. PMID: 27250739.
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
24. Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. Deaths
Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014. Annals of the
American Thoracic Society. In press.
Letters to the Editor:
1. Vetter M, Vinnard C, Wadden T. 2009. Perioperative safety and bariatric surgery. New
England Journal of Medicine. 361(19): 1910. PMID: 19890138.
2. Vinnard C. Racial differences in rates of severe sepsis. Journal of the American Medical
Association. 304(14):1556. PMID: 20940380.
Book Chapters:
1. Vinnard C, Blumberg E. Endocrine and Metabolic Aspects of Tuberculosis. In: Tuberculosis
and Nontuberculous Mycobacterial Infections, Sixth Edition. Schlossberg D. ASM Press,
Washington, DC. 2011.
Research Support:
Active (direct costs):
1K23AI102639-02 (Vinnard)
9.0 Calendar
NIH-NIAID
$112,000
Rifampin Malabsorption in HIV+ Patients: Mechanisms and Recovery after HAART
This 5-year mentored career development award will provide the PI with pharmacometrics training
in the area of HIV/TB co-infection, and will test the hypotheses that markers of gut damage among
HIV/TB patients will be associated with rifampicin malabsorption, and that partial recovery of
rifampicin absorption will occur following the initiation of HAART.
Role: PI
Completed:
1R21AI104441-01 (Bisson)
0.5 Calendar
NIH-NIAID
$246,256
Immune Activation and Isoniazid Metabolism in HIV/TB
This project will test the hypothesis that increased immune activation in HIV is associated with
decreased INH clearance in patients with HIV and pulmonary tuberculosis.
Role: Co-I
Intramural (Vinnard)
0.5 Calendar
Clinical and Translational Research Institute , Drexel University
$75,000
A Novel Method to Detect Rifamycins in Biologic Samples
In this project we will develop a novel approach to tag rifamycin compounds with a fluorescent dye,
with the long-term goal of developing an alternate method for therapeutic drug monitoring in
resource-limited settings.
Role: PI
Janssen (Vinnard)
0.5 Calendar
Investigator Initiated Award
$77,615
This project will provide pilot data towards testing the hypothesis that markers of gut inflammation
Christopher Vinnard
31 Eglantine Ave
Pennington, NJ 08534
(215) 983-0471
[email protected]
and damage are associated with rifampicin malabsorption among HIV-infected patients.
Role: PI
Gates (Vinnard)
05/01/2012 - 12/31/2013
0.0 Calendar
Bill & Melinda Gates Foundation
$100,000
A Novel Diagnostic Test for Poor Anti-TB Drug Bioavailability
The overall goal of this project is to explore urine colorimetry as an alternate diagnostic approach
for the detection of low anti-tuberculosis drug bioavailability.
Role: PI
Intramural (Vinnard)
6/1/2012 – 12/31/2012
0.0 Calendar
Clinical and Translational Pilot Research Grant Competition
$25,000
Rifampicin Transport Across an In Vitro Model of the Intestinal Barrier
This award supports a program to identify specific rifampicin uptake transporters in Caco-2 cells as
an in-vitro model for the intestinal barrier.
Role: PI
5T32AI055435-07 (Strom)
7/1/2009 – 6/30/2011
NIH-NIAID
Infectious Disease Epidemiology
The major goal of this grant is to train clinicians to be rigorous and independent academic
investigators able to use the range of approaches available in epidemiology to address research
issues.